NCT03891784View on ClinicalTrials.gov

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2019

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2027

Conditions
Advanced Digestive System Neuroendocrine NeoplasmDigestive System Neuroendocrine TumorForegut Neuroendocrine TumorHindgut Neuroendocrine TumorLocally Advanced Unresectable Digestive System Neuroendocrine NeoplasmMetastatic Digestive System Neuroendocrine NeoplasmMidgut Neuroendocrine TumorPancreatic Neuroendocrine TumorRefractory Digestive System Neuroendocrine Neoplasm
Interventions
DRUG

Abemaciclib

Given PO

Trial Locations (2)

80217

University of Colorado, Denver

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

University of Washington

OTHER